BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts
It was designed to be the oral fix for hereditary angioedema (HAE) — a rare, potentially life-threatening genetic disorder — but BioCryst Pharmaceutical’s experimental capsule has underwhelmed in a pivotal late-stage study, despite meeting the primary endpoint.
Two doses of the oral drug, BCX7353, (110 mg and 150 mg) were investigated in a 121-patient, placebo-controlled trial called APeX-2 for the prevention of angioedema attacks — recurrent episodes of severe swelling commonly in the limbs, face, intestinal tract, and airway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.